baber/WOPTO huggingface dataset:
Patent JP-H037670-B2 (JP)
IPC: C07D215/18
Filed: 1981-12-29
Abstract: Novel quinolylacetic acid compounds of the formula (I):   <IMAGE> (I) wherein R1 is a member selected from the group consisting of hydrogen atom, a lower alkyl group having 1 to 4 carbon atoms, and a lower alkyl group having 1 to 4 carbon atoms substituted with an aromatic group having a substituent; R2 is a member selected from the group consisting of hydrogen atom and a lower alkyl group having 1 to 4 carbon atoms; R3 is a member selected from the group consisting of hydrogen, a halogen atom, an alkyl group having 1 to 8 carbon atoms, and an alkenyl group having 2 to 8 carbon atoms; R4 and R5, carpable of cyclization, are each a member selected from the group consisting of hydrogen atom and a lower alkyl group having 1 to 4 carbon atoms; R6 is a member selected from the group consisting of hydrogen atom an alkyl group having 1 to 8 carbon atoms, an alkenyl group having 2 to 5 carbon atoms, an alkynyl group having 3 to 8 carbon atoms, an aralkyl group, a substituted aralkyl group, an aliphatic or aromatic acyl group, and a substituted aliphatic or aromatic acyl group; and A is a member selected from the group consisting of hydrogen atom and an oxo group; the broken line denoting a second bond or no bond when A is a hydrogen atom and denoting no bond when A is an oxo group, and pharmaceutically acceptable salts thereof.
Patent JP-S6327223-B2 (JP)
IPC: B60Q1/05
Filed: 1983-11-21
Abstract: PURPOSE:To prevent irradiation of an opposing running car with dazzling light yielded by the residual light of a head lamp, even if a vehicle is of a type in which it has a head lamp having an irradiation surface which is shielded in a direction extending from the front of a vehicle to the upper thereof. CONSTITUTION:In a third condition in which a contact T22C of a lighting switch 22 is connected to contacts t and H, a diode D5 in a delay circuit 10 is earthed through a contact H of the switch 22. In which case, since a relay 21 is excited, a contact 21 is opened, and capacitors C1, C2, and C3 are charged, in case the third condition is returned at a breath to a first condition in which the contact piece T22C is connected in an OFF state to a contact E, and thereafter, a contact T21 of the relay 21 is closed, and head lamps 15 and 16 are shielded and driven. Thus, since, after the lamps 15 and 16 are lighted OFF and a residual light disapears completely, the lamps are shielded and driven by means of motors M1 and M2, an opposing running vehicle is prevented from irradiation with a dazzling light.
Patent JP-3366289-B2 (JP)
IPC: C07D211/42
Filed: 1999-08-09
Granted: 2003-01-14
Abstract: The present invention concerns a process for the preparation of a compound of formula 1 or a salt thereof <CHEM>  characterised in that the process comprises     a) hydroboration of a compound of formula 2 <CHEM> in which formulae A is arylene; R<1> is -C*R<3>R<4>R<5>; R<2> is -O-alkyl, -O-cycloalkyl, -O-alkenyl, -O-aryl, -O-aralkyl, -O-aralkoxyalkyl, -O-alkylsulfonyl, -O-arylsulfonyl, chlorine, bromine or iodine; R<3> is hydrogen; R<4> is aryl; R<5> is alkyl, cycloalkyl, aryl, alkoxyalkyl or hydroxyalkyl; and wherein C* is an asymmetric carbon atom; b) optionally followed by isolation of the desired stereoisomer.
Patent JP-H0758928-B2 (JP)
IPC: H04B7/08
Filed: 1987-10-09
Abstract: For diversity reception from a plurality of antennas, particularly in an automotive vehicle (FIG. 4), the respectively received signals are mixed with a local oscillator signal to form a plurality of IF signals (u1 . . . un). The respective IF signals are weighted with a weighting coefficient which is derived from a sum circuit of all the IF signals, and the respective IF signal, which weighting circuit includes an integrator to minimize temporal variations in the amplitude of the sum signal. The sum signal forms the actual IF signal, for further processing, and demodulating to derive an audio signal. Preferably, the signals from the antennas are branched, and the branch signals phase-shifted 90 DEG , which, again, are weighted by similarly generated weighting coefficients, and the weighted, phase-shifted signals are combined in the adding or summing circuit (70) to form said eventual IF signal for demodulation.
Patent JP-3130342-B2 (JP)
IPC: C07D215/14
Filed: 1991-10-04
Granted: 2001-01-31
Abstract: An inhibitor of atherosclerotic intimal thickening, which contains an effective amount of a compound of the formula (I): <CHEM> wherein ring X is phenyl, substituted phenyl or 5- or 6-membered heterocyclic aryl; each of R<1> and R<2> which are independent of each other, is hydrogen, C<5> PI 3/4  alkyl, C<7> PI 1/2  cycloalkyl, C<5> PI <7> alkoxy, n-butoxy, i-butoxy, sec-butoxy, tert-butoxy, R<2>0R<2><1>N- (wherein each of R<2>0 and R<2><1> which are independent of each other, is hydrogen or C<5> PI <7> alkyl), trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoro, chloro, bromo, phenyl, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-tert-butylsilyloxy, hydroxymethyl or -O(CH<6>)POR<2><2> (wherein R<2><2> is hydrogen or C<5> PI <7> alkyl, and P is 1, 2, or 3); or R<1> and R<2> together form -CH=CH-CH=CH- or methylenedioxy, when they are at the o-position to each other; R<3> is hydrogen, C<5> PI 3/4  alkyl, C<6> PI 1/4  alkenyl, C<7> PI 1/2  cycloalkyl, C psi  PI 1/2  cycloalkenyl or <CHEM> (wherein R7 is hydrogen, C<5> PI 3/4  alkyl, C<5> PI 3/4  alkoxy, C<5> PI <7> alkylthio, chloro, bromo, fluoro, chloromethyl, trichloromethyl, trifluoromethyl, trifluoromethoxy, trichloromethoxy, difluoromethoxy, phenoxy, benzyloxy, hydroxy, trimethylsilyloxy, diphenyl-tert-butylsilyloxy or hydroxymethyl); or C<5> PI <7> alkyl substituted by one <CHEM> (wherein R7 is as defined above) and zero, one or two C<5> PI <7> alkyl; Y is -CH<6>-, -CH<6>CH<6>-, -CH=CH-, -CH<6>-CH=CH-, -CH=CH-CH<6>-, -C(CH<7>)=CH- or -CH=C(CH<7>)-;     Z is -Q-CH<6>-W-CH<6>-CO<6>R<1><2>, <CHEM>  (wherein Q is -C(O)-, -C(OR<1><3>)<6>- or -CH(OH)-,     W is -C(O), -C(OR<1><3>)<6>- or -C(R<1><1>)(OH)-,     R<1><1> is hydrogen or C<5> PI <7> alkyl, R<1><2> is hydrogen, R<1>4 (wherein R<1>4 is alkyl of a chemically or physiologically hydrolyzable alkyl ester moiety, NHR<2><3>R<2>4R<2>5 (wherein each of R<2><3>, R<2>4 and R<2>5 is hydrogen or C<5> PI <8> alkyl), sodium, potassium or 1/2 calcium), each R<1><3> is independently primary or secondary C<5> PI 1/4 alkyl, or two R<1><3> together form -(CH<6>)<6>- or -(CH<6>)<7>-, and each of R<1>5 and R<1>6 which are independent of each other, is hydrogen atom or C<5> PI <7> alkyl, or R<1>5 and R<1>6 together form -(CH<6>)<6>- or -(CH<6>)<7>-.
Patent JP-3961582-B2 (JP)
IPC: C03C17/36
Filed: 1995-10-25
Granted: 2007-08-22
Abstract: A laminated structure for windows, particularly on vehicles, comprises a transparent substrate (1) on which are deposited three layers of ZnS (2,4,6) sandwiching two layers of Ag (3,5). Ag layer (3) closest to the substrate is thinner than layer (5). A further transparent substrate (8) may be bonded by polyvinylbutyral layer (7) on to uppermost layer (6) of ZnS. To assist bonding very thin layers of another metal, alloy or oxide thereof may be located between substrate (1) and layer (7) and the adjacent ZnS layers (2) and (6).
Patent JP-H07108861-B2 (JP)
IPC: C07C31/125
Filed: 1986-11-26
Abstract: Preparation of C3- to C25-alkanols by catalytic hydrogenation of corresponding crude C3- to C25-alkanols, as obtained in the cobalt-catalyzed hydroformylation of C2- to C24-olefins, by partial 80-95% hydrogenation conversion in a first stage using a silica supported nickel and molybdenum oxide catalyst and then completing the conversion in a second stage using a cobalt catalyst containing copper, manganese, molybdenum and,optionally other activating additives. The process is especially adapted to the economic preparation of C9-C11- and C13-C15-alkanols which are used to prepare high-grade plasticizer esters.
Patent JP-2645608-B2 (JP)
IPC: A61F7/12
Filed: 1990-10-24
Granted: 1997-08-25
Abstract: The treatment apparatus comprises, in addition to a probe (2) to be introduced into the body orifices or body cavities, a control device (1) which is equipped in a conventional manner with a mains-chargeable battery. The control circuit is provided with means (intermittent current impulse switching) whose effect is such that the heating device of the probe (2) emits the heat in the form of intermittent heat pulses of adjustable magnitude. The apparatus is used for the therapeutic treatment of diseases of the walls (tissues) of body cavities, such as, for example, haemorrhoids, prostates. <IMAGE>
Patent JP-3382103-B2 (JP)
IPC: C07D239/00
Filed: 1996-11-06
Granted: 2003-03-04
Abstract: Crystalline calcium salt of (6R,S)-, (6R)- and (6S)-tetrahydrofolic acid. Also claimed is the magnesium salt. The crystallisation is preferably performed in a polar medium, preferably water or a mixture of water and an organic solvent most preferably acetic acid or a lower alcohol, at pH 7-10 at an elevated temperature and/or from a dilute solution
Patent JP-2652645-B2 (JP)
IPC: F04B43/04
Filed: 1987-12-10
Granted: 1997-09-10
Abstract: A ferromagnetic-fluid pump (1) includes a hollow body (2; 102) having a substantially rigid structure and an internal diaphragm (3; 103) dividing said body in two cavities. Each cavity has an inlet (16, 17; 140, 141) and an outlet (18, 19; 142, 143) opening provided with one-way valve. One edge of said diaphragm is hinged (4; 104) on the body structure while its opposite edge is spaced from the adjacent inner surface of said body. Said cavities are partially filled with a ferromagnetic fluid (12, 112) which seals said diaphragm in respect of the inner surface of said body. At least one electric winding (6-9; 150-153, 160-163, 170-173, 180-183) is provided onto both sides of said diaphragm and onto the two inner surfaces of said body facing said diaphragm. Said windindg are operative to generate a variable magnetic fluid so that said diaphragm oscillates.
Patent JP-2780032-B2 (JP)
IPC: G06F11/07
Filed: 1988-12-22
Granted: 1998-07-23
Abstract: A multiprocessor digital data processing system comprises a plurality of processing cells (18A to 18R, 34A to 34F, 38A, 38B) arranged in a hierarchy of rings (12A to 12F, 14A and 14B, 16). The system selectively allocates storage and moves exclusive data copies from cell to cell in response to access requests generated by the cells. Routing elements are employed to selectively broadcast data access requests, updates and transfers on the rings.
Patent JP-2812670-B2 (JP)
IPC: G01S7/52
Filed: 1995-11-21
Granted: 1998-10-22
Abstract: The method for producing three dimensional ultrasonic images of the interior of a body involves transmitting ultrasonic waves over a volumetric region of the interior of the body, receiving ultrasonic Doppler information signals from spatial locations within the region and processing the ultrasonic Doppler information signals to determine the Doppler power intensity received from the locations within the region. The Doppler power intensity is displayed on a spatial basis in a three dimensional presentation. The processing involves processing the ultrasonic Doppler information signals to determine the maximum Doppler power intensity received from the locations within the region. The displaying involves displaying the maximum Doppler power intensity of the locations on a spatial basis in a three dimensional presentation.
Patent JP-3597238-B2 (JP)
IPC: H05K1/02
Filed: 1994-12-14
Granted: 2004-12-02
Abstract: PURPOSE: To eliminate leak of emitted light from the area other than the corresponding display holes by providing a light shading means between a first surface and a substrate in such a manner as transmitting the light emitted from a surface mounting light emitting element to the second surface of the panel only from the corresponding display holes. CONSTITUTION: A dummy chip 5 is provided between SMD type LED 1, 2. This dummy chip 5 is formed, for example, with a light shading plate such as a metal plate. The emitted lights of SMD LED 1, 2 pass to the side of external surface 4b of a cosmetic panel 4 through the corresponding display holes 4c, 4d as shown in 11a, 12a. The light beam reflected by the recessed surfaces 5c, 5d passes to the side of the external surface 4b of the panel 4 via the display holes 4c, 4d corresponding to SMD LED 1, 2 as shown in 11c, 12c. That is, the diffused light beams to each direction can be shaded, that is, leak of light beam can be prevented by providing a dummy chip 5 between the SMD LED 1, 2.
Patent JP-3105806-B2 (JP)
IPC: G06F21/34
Filed: 1996-12-20
Granted: 2000-11-06
Abstract: The security procedure makes use of a smart card held by an authorised subscriber. The card is inserted into the terminal to allow it to operate. There are two modes, a normal mode when any authorised card need only be inserted into the terminal and a locked mode, when the terminal can be used only with a specific card. The smart card has locking data stored in a particular part of its memory. When operated in locked mode there is an initial stage of authentication of the user card carried out by the terminal. The terminal applies an algorithm to the data read from the card, and allows operation only if the result matches a values stored in the terminal.
Patent JP-3637463-B2 (JP)
IPC: F01N3/34
Filed: 1995-12-14
Granted: 2005-04-13
Abstract: A dual wall, air gap exhaust manifold has an integral inlet connecting flange 16) defining an elongated, internal , air injection passageway (36) enclosed by an L-shaped plate (50) welded over an elongated slot in the flange to form the elongated passageway, the L-shaped plate also being welded over a series of short channels (42) which extend between the elongated passageway and the manifold inlet openings. The elongated passageway has an air inlet connector (60). The spaced dual walls (20), 22) of the manifold runners are joined together at the flange openings, just downstream of the channels. <IMAGE>
Patent JP-3404716-B2 (JP)
IPC: C12Q1/686
Filed: 1998-12-17
Granted: 2003-05-12
Abstract: A DNA polymerase having an amino acid sequence comprising substantially the same amino acid sequence as that of Thermus aquaticus or Thermus flavus DNA polymerase, excluding the N-terminal 280 amino acid residues of Thermus aquaticus DNA polymerase or the N-terminal 279 amino acid residues of Thermus flavus DNA polymerase, recombinant DNA sequences encoding said DNA polymerases, vectors comprising said DNA sequences, and host cells containing such vectors. A formulation of thermostable DNA polymerases comprising a majority component comprised of at least one thermostable DNA polymerase of the type described above, wherein the DNA polymerase lacks 3'-exonuclease activity, and a minority component comprised of at least one thermostable DNA polymerase exhibiting 3'-exonuclease activity, and an improved method for amplifying nucleic acid sequences by polymerase chain reaction wherein the above formulation is mixed and used to catalyze primer extension, are also provided.
Patent JP-3913951-B2 (JP)
IPC: C09K23/42
Filed: 1999-12-27
Granted: 2007-05-09
Abstract: A nanoemulsion comprising a dispersed lipid phase in an aqueous phase with lipid globules having an average size of less than 100 nm contains:  (1) a surfactant such as ethoxylated fatty esters or ethers; and  (2) at least one oil with a molecular weight of more than 400 and at a lipid phase/surfactant weight ratio of 2-10. Independent claims are also included for:  (1) a topical composition comprising the above described composition;  (2) an ophthalmic support comprising the above described composition;  (3) a pharmaceutical composition comprising the above described composition;  (4) a cosmetic method for the care and/or hydration of the skin, mucosa and/or scalp by applying the above described composition; and  (5) the preparation of the composition by mixing an aqueous phase and a lipid phase at 10-80 degrees C and homogenizing the mixture at 6 x 10<7>-18 x 10<7> Pa.
Patent JP-3437182-B2 (JP)
IPC: H04N1/191
Filed: 1992-06-05
Granted: 2003-08-18
Abstract: PCT No. PCT/US92/04734 Sec. 371 Date Feb. 2, 1994 Sec. 102(e) Date Feb. 2, 1994 PCT Filed Jun. 5, 1992 PCT Pub. No. WO92/22109 PCT Pub. Date Dec. 10, 1992A laser beam scanning apparatus employs a movable reflector (32) having a large number of flat reflective sides (44) a deflector (16) which shifts the laser beam (10) at high speed across a plurality of the reflective sides (44). The movement of reflector (32) is synchronized with the deflection of the laser beam (10) to produce a desired scan pattern in a first scan direction (X). The reflective sides (44) of the movable reflector (32) may be angled relative to each other in a second direction (Y) to produce different scan lines thereby providing an X-Y scan pattern. The combined high speed beam deflection and motion of the reflector (32) provide scanning of the beam (10) in parallel scan segments thereby providing high scanning speed of the beam with a high degree of resolution.
Patent JP-3589664-B2 (JP)
IPC: C07C401/00
Filed: 1993-06-30
Granted: 2004-11-17
Abstract: PCT No. PCT/EP93/01735 Sec. 371 Date Mar. 16, 1995 Sec. 102(e) Date Mar. 16, 1995 PCT Filed Jun. 30, 1993 PCT Pub. No. WO94/00429 PCT Pub. Date Jan. 6, 199422-En-24-a-oxa derivatives in the vitamin D series of general formula I    <IMAGE>  (I)  in which R1, R2 and R4, independently of one another, each mean a hydrogen atom, an alkanoyl group with 1 to 9 carbon atoms or an aroyl group, R3 mean a hydrogen atom each or a linear or branched alkyl group each with 1 to 4 carbon atoms, a trifluoromethyl group each or a saturated or unsaturated carbocyclic or heterocyclic 3-, 4-, 5- or 6-membered ring formed together with the tertiary carbon atom, and X means an alkylene radical -(CH2)n-with n=1, 2 or 3, process for their production and their pharmaceutical use for treating hyperproliferative diseases are disclosed.
Patent JP-3300368-B2 (JP)
IPC: C07K1/113
Filed: 1997-07-04
Granted: 2002-07-08
Abstract: A method of selectively acylating an insulin, an insulin analogue or a precursor thereof having a free  epsilon -amino group of a Lys residue contained therein and at least one free  alpha -amino group which method comprises reacting the  epsilon -amino group with an activated amide in a polar solvent in the presence of a base.
Patent JP-H0640874-B2 (JP)
IPC: A61B17/00
Filed: 1990-04-06
Abstract: PCT No. PCT/AU90/00135 Sec. 371 Date Dec. 2, 1991 Sec. 102(e) Date Dec. 2, 1991 PCT Filed Apr. 6, 1990 PCT Pub. No. WO90/11723 PCT Pub. Date Oct. 18, 1990.A microsurgical instrument comprising a generally cylindrical handpiece (10) split longitudinally to provide two semi-cylindrical parts (12, 13) which are pivotally mounted at a first end thereof, to a central support member (14), for symmetrical pivotal movement at a second end towards and away from each other. A spring (26) biases the parts (12, 13) away from each other. A spindle (11) extends beyond the second end, comprising a pair co-axial shafts (16, 17) which are connected at the first end with respective levers (23, 24) to respective handpiece parts (12, 13) and at the second end to a functional tip of scissor, forceps, or the like, each jaw member of such a tip being connected to only one of the co-axial shafts (16, 17). Squeezing of the handpiece parts (12, 13) together causes simultaneous and symmetrical rotation of the co-axial shafts (16, 17) in opposite directions whereby the jaws of the functional tips are activated symmetrically and in unison.
Patent JP-2549225-B2 (JP)
IPC: C07K14/235
Filed: 1991-04-03
Granted: 1996-10-30
Abstract: A component vaccine against disease caused by infection by Bordetella pertussis, characterized by:   as a first component, purified pertactin having no detectable adenylate cyclase activity, as at least one additional component thereof, at least one other purified B. pertussis antigen which is pertussis toxin (PT), filamentous haemagglutinin (FHA) and/or agglutinogens; as at least two further components thereof, at least two other purified non-Bordetella antigens which are diphtheria toxoid (D) and tetanus toxoid (T); and a pharmaceutically-acceptable carrier therefor.
Patent JP-3922307-B2 (JP)
IPC: A61P25/08
Filed: 1995-07-27
Granted: 2007-05-30
Abstract: PCT No. PCT/DE95/00981 Sec. 371 Date Feb. 11, 1997 Sec. 102(e) Date Feb. 11, 1997 PCT Filed Jul. 27, 1995 PCT Pub. No. WO96/04897 PCT Pub. Date Feb. 22, 1996The invention relates to the use of selegiline (=L-N-(1-phenylisopropyl)-N-methyl-N-propynylamine) or pharmaceutically utilizable salts thereof in pharmaceuticals with an antiepileptic effect.
Patent JP-3942641-B2 (JP)
IPC: A61P29/00
Filed: 1997-07-29
Granted: 2007-07-11
Abstract: A synergistic combination of an IL-2 transcription inhibitor (e.g., cyclosporin A or FK506) and 40-O-(2-hydroxyethyl)-rapamycin is provided, which is useful in the treatment and prevention of transplant rejection and also certain autoimmune and inflammatory diseases, together with novel pharmaceutical compositions comprising an IL-2 transcription inhibitor in combination with a rapamycin, e.g., 40-O-(2-hydroxyethyl)-rapamycin.
Patent JP-3398380-B2 (JP)
IPC: C07K14/445
Filed: 1992-05-18
Granted: 2003-04-21
Abstract: The invention relates to recombinant DNA molecules comprising a Dictyostelium discoideum homologous promoter region, a heterologous DNA sequence with a Dictyostelium discoideum homologous peptide sequence capable of functioning as a leader peptide sequence positioned upstream thereof and in proper reading frame therewith, and a Dictyostelium discoideum homologous termination region, the heterologous DNA sequence encoding the desired functional polypeptide or intermediate thereof, said DNA sequence being positioned downstream from the promoter region and said termination region being positioned downstream from the DNA sequence. The invention also provides recombinant dictyostelid hosts as well as methods for preparing recombinant DNA molecules of the invention and for expressing recombinant polypeptides encoded by said recombinant DNA molecules in dictyostelid hosts. The invention in particular relates to the expression of the CS protein of Plasmodium falciparum.
Patent JP-3711408-B2 (JP)
IPC: C23C4/12
Filed: 1995-09-25
Granted: 2005-11-02
Abstract: Atomized metal is deposited metal onto a substrate so as to cause at least partial solidification of the deposited metal; further atomized metal is deposited onto the partially solidified deposited metal on the substrate; and the metal deposited onto the partially solidified deposited metal is allowed to fully solidify on the substrate; the cooling of the further deposited metal, and the composition of the metal and/or of a gas used in the atomization of the further atomized metal being tailored such that volumetric contraction on solidification and cooling of the further deposited metal is compensated for, when the deposited metal has been cooled to ambient temperature, by volumetric expansion in a reaction or phase change in the further deposited metal.
Patent JP-3013939-B2 (JP)
IPC: C07F9/10
Filed: 1992-06-03
Granted: 2000-02-28
Abstract: PCT No. PCT/SE92/00374 Sec. 371 Date Dec. 30, 1993 Sec. 102(e) Date Dec. 30, 1993 PCT Filed Jun. 3, 1992 PCT Pub. No. WO92/21384 PCT Pub. Date Dec. 10, 1992The present invention refers to a phospholipid-based compound, that is a phospholipid to which an X-ray contrast-giving moiety has been covalently linked, liposomes comprising said compound as well as the use of said liposomes as a diagnostic or contrast agent.